Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Amarin slides despite fourth quarter beat on strong Vascepa demand » 11:19
02/26/20
02/26
11:19
02/26/20
11:19
TEVA

Teva

$13.08 /

-0.17 (-1.28%)

, HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

, HKMPY

Hikma

$0.00 /

+ (+0.00%)

, RDY

Dr. Reddy's

$43.14 /

+0.44 (+1.03%)

, AMRN

Amarin

$16.44 /

-1.1 (-6.27%)

Shares of Amarin (AMRN)…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
H.C. Wainwright reiterates $51 price target on Amarin shares post Q4 results » 07:20
02/26/20
02/26
07:20
02/26/20
07:20
AMRN

Amarin

$17.54 /

-0.05 (-0.28%)

, RDY

Dr. Reddy's

$42.70 /

-0.89 (-2.04%)

, HKMPY

Hikma

$0.00 /

+ (+0.00%)

, TEVA

Teva

$13.25 /

+0.55 (+4.33%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Andrew Fein reiterates a Buy rating on Amarin (AMRN) with a $51 price target following the company's Q4 results. Amarin has asserted its confidence both in its intellecutal property and its intention to vigorously defend its patents, Fein tells investors in a research note. The analyst points out that two of the original four Abbreviated New Drug Application filers currently remain, Dr. Reddy's (RDY) and Hikma (HKMPY), while Teva (TEVA) has settled with Amarin to enter the market in August 2029 and Apotex has determined not to litigate. Fein continues to believe in the feasibility of settlement with a court decision expected in March. Meanwhile, Vascepa's positive commercial traction as an omega-3 therapeutic "represents the tip of the iceberg for the treatment," the analyst writes in a research note.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
On The Fly
Amarin rises as Citi says Buy on selloff, accelerating Vascepa sales » 11:20
02/18/20
02/18
11:20
02/18/20
11:20
AMRN

Amarin

$17.93 /

+0.3 (+1.70%)

, RDY

Dr. Reddy's

$45.37 /

-0.13 (-0.29%)

, HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

Shares of Amarin (AMRN)…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Dr. Reddy's to acquire select business divisions of Wockhardt in India » 05:23
02/12/20
02/12
05:23
02/12/20
05:23
RDY

Dr. Reddy's

$44.54 /

+0.6 (+1.37%)

Dr. Reddy's…

Dr. Reddy's Laboratories announced that it has entered into a definitive agreement with Wockhardt Limited to acquire select divisions of its branded generics business in India and a few other international territories of Nepal, Sri Lanka, Bhutan and Maldives for a consideration of Rs.1850 Crores.The business comprises of a portfolio of 62 brands in multiple therapy areas such as Respiratory, Neurology, VMS, Dermatology, Gastroenterology, Pain and Vaccines, which would transfer to Dr. Reddy's along with related sales and marketing teams; and the manufacturing plant located in Baddi, Himachal Pradesh with all plant employees. The business undertaking is being transferred on a slump sale basis. The transaction is expected to be closed in the first quarter of the financial year 2020-21.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Dr. Reddy's announces launch of Trientine Hydrochloride Capsules USP in U.S. » 05:30
02/07/20
02/07
05:30
02/07/20
05:30
RDY

Dr. Reddy's

$44.82 /

+0.36 (+0.81%)

Dr. Reddy's…

Dr. Reddy's announced the launch of Trientine Hydrochloride Capsules USP, 250 mg, a therapeutically equivalent generic version of Syprine Capsules, approved by the FDA. Dr. Reddy's Trientine Hydrochloride Capsules USP, 250 mg are available in 100 count bottles.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a month ago
Recommendations
Jefferies confident Amarin will win patent trial, sees up to 20% rally » 09:18
01/29/20
01/29
09:18
01/29/20
09:18
AMRN

Amarin

$20.26 /

+0.59 (+3.00%)

, RDY

Dr. Reddy's

$44.46 /

+0.25 (+0.57%)

, HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

Court proceedings for the…

Court proceedings for the Amarin (AMRN) versus Dr. Reddy's (RDY) and Hikma Pharmaceuticals (HKMPF) case have ended, following seven days of expert witness testimony, Jefferies analyst Michael Yee tells investors in a research note. The judge did not provide a preliminary ruling or hint at which way she is ruling, but she did state the written ruling will be made by March 31, Yee points out. With the proceedings completed, and Dr. Reddy's and Hikma having presented their best case, Yee is now more confident that Amarin is likely to prevail, "removing the chief overhang on the stock." Amarin shares have been relatively range bound the last month despite positive news on the competitive front with two key competitor trials having failed, Yee contends. He attributes this to uncertainty associated with the patent trial and the potential risk for Reddy's and Hikma, two prospective generics for Amarin's Vascepa, to present some "bombshell" evidence. However, the analyst now thinks it will be hard for the judge to not rule in favor of Amarin. Yee sees the stock up 10%-20% on a positive ruling and keeps a Buy rating on Amarin with a $30 price target. The stock closed Tuesday at $20.26.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Dr. Reddy's downgraded to Outperform from Buy at CLSA » 05:55
01/28/20
01/28
05:55
01/28/20
05:55
RDY

Dr. Reddy's

$44.21 /

+2.21 (+5.26%)

CLSA analyst Alok Dalal…

CLSA analyst Alok Dalal downgraded yesterday afternoon Dr. Reddy's to Outperform from Buy with a price target of INR 3,450. The company's EBITDA beat fiscal Q3 expectations but a large impairment drove a net profit miss, Dalal tells investors in a post-earnings research note. The stock's valuation "offers limited room to slip up" and already "bakes in positives," the analyst contends.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Dr. Reddy's downgraded to Outperform from Buy at CLSA » 15:56
01/27/20
01/27
15:56
01/27/20
15:56
RDY

Dr. Reddy's

$44.49 /

+2.49 (+5.93%)

CLSA downgraded Dr.…

CLSA downgraded Dr. Reddy's to Outperform from Buy.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

On The Fly
Amarin seen in 'good position' as Vascepa patent trial proceeds » 11:59
01/21/20
01/21
11:59
01/21/20
11:59
AMRN

Amarin

$21.49 /

+1.58 (+7.94%)

, RDY

Dr. Reddy's

$42.64 /

+0.2 (+0.47%)

Following the fourth day…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Amarin in 'good position' as 'heated' patent trial continues, says Jefferies » 08:15
01/16/20
01/16
08:15
01/16/20
08:15
AMRN

Amarin

$19.38 /

+0.06 (+0.31%)

, RDY

Dr. Reddy's

$41.63 /

-0.25 (-0.60%)

Jefferies analyst Michael…

Jefferies analyst Michael Yee said the third day of Amarin's (AMRN) patent trial versus Hikma and Dr. Reddy's (RDY) focused on the claim of nonobviousness and examination of the defense's witness, adding that cross-examination "went well" in his view for Amarin. Barring some new evidence or "radical interpretation" by Judge Miranda Du, Yee thinks Amarin is in a "good position" and believes the company is likely to prevail on upholding the patent given his view that the burden of proof is "already high" for obviousness. The analyst, who noted that the trial will last until the end of January and a decision is expected around March or April, has a Buy rating on Amarin shares.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.